One of the most persistent dilemmas in cancer immunotherapy has been that the drug combinations most likely to eliminate tumors are also the ones most likely to cause serious immune-related harm. A randomized phase 1b trial published in Nature now proposes a route-of-administration solution that may fundamentally reframe how oncologists think about checkpoint inhibitor dosing strategy.
The NIVIPIT trial enrolled 61 patients with previously untreated metastatic melanoma and randomly assigned them 2:1 to receive intravenous nivolumab (anti-PD1 at 1 mg/kg) paired with either intratumoral ipilimumab (anti-CTLA4 at 0.3 mg/kg, injected directly into a lesion) or standard intravenous ipilimumab (3 mg/kg). The primary endpoint — grade 3 or 4 treatment-related adverse events at six months — was decisively met: severe toxicity occurred in only 22.6% of the intratumoral arm versus 57.1% in the intravenous arm, a rate comparable to anti-PD1 monotherapy alone. Despite using a ten-fold lower systemic dose, efficacy was not sacrificed: objective response rates reached 65.7% for injected lesions and 50% for uninjected lesions, confirming that the abscopal-like effect extended beyond the injection site. Baseline immune profiling identified pro-tumoral activated regulatory T cells and M2 macrophages as predictors of durable benefit, and depletion of intratumoral Treg cells was observed specifically in durable responders.
This finding is potentially paradigm-shifting for checkpoint inhibitor therapy. The standard nivolumab-ipilimumab combination has long been hampered by a roughly 55–60% rate of serious adverse events, frequently forcing dose reductions or discontinuation. By concentrating CTLA4 blockade locally while maintaining systemic PD1 inhibition, NIVIPIT achieves comparable anti-tumor activity with a toxicity profile that could meaningfully expand eligibility to patients previously considered too frail for combination therapy. The identification of Treg and M2 macrophage signatures as predictive biomarkers also adds a clinically actionable layer, though validation in larger cohorts is essential. Limitations include the modest sample size, single tumor type, and phase 1b design — larger confirmatory trials will be necessary before this approach enters routine practice. Still, as a proof-of-concept, this is among the more consequential immunotherapy delivery innovations in recent years.